Literature DB >> 11118040

Direct evidence for the contribution of activated N-ras and K-ras oncogenes to increased intrinsic radiation resistance in human tumor cell lines.

E J Bernhard1, E J Stanbridge, S Gupta, A K Gupta, D Soto, V J Bakanauskas, G J Cerniglia, R J Muschel, W G McKenna.   

Abstract

Transformation with ras oncogenes results in increased radiation sur vival in many but not all cells. In addition, prenyltransferase inhibitors which inhibit ras proteins by blocking posttranslational modification radiosensitize cells with oncogenic ras. These findings suggest that oncogenic ras contributes to intrinsic radiation resistance. However, because introduction of ras oncogenes does not increase radiation survival in all cells and because prenyltransferase inhibitors target molecules other than ras, these studies left the conclusion that ras increases the intrinsic radi ation resistance of tumor cells in doubt. Here we show that genetic inactivation of K- or N-ras oncogenes in human tumor cells (DLD-1 and HT1080, respectively) leads to increased radiosensitivity. Reintroduction of the activated N-ras gene into the HT1080 line, having lost its mutant allele, resulted in increased radiation resistance. This study lends further support to the hypothesis that expression of activated ras can contribute to intrinsic radiation resistance in human tumor cells and extends this finding to the K- and N- members of the ras family. These findings support the development of strategies that target ras for inactivation in the treatment of cancer.

Entities:  

Mesh:

Year:  2000        PMID: 11118040

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  64 in total

1.  Preclinical study of the DNA repair inhibitor Dbait in combination with chemotherapy in colorectal cancer.

Authors:  Flavien Devun; Guilhem Bousquet; Julian Biau; Aurélie Herbette; Christophe Roulin; Frédérique Berger; Jian-Sheng Sun; Sylvie Robine; Marie Dutreix
Journal:  J Gastroenterol       Date:  2011-11-09       Impact factor: 7.527

2.  Signaling pathways in NSCLC as a predictor of outcome and response to therapy.

Authors:  Anjali K Gupta; Daniel E Soto; Michael D Feldman; Jeffrey D Goldsmith; Rosemarie Mick; Stephen M Hahn; Mitchell Machtay; Ruth J Muschel; W Gillies McKenna
Journal:  Lung       Date:  2004       Impact factor: 2.584

3.  Enhanced MET Translation and Signaling Sustains K-Ras-Driven Proliferation under Anchorage-Independent Growth Conditions.

Authors:  Saori Fujita-Sato; Jacqueline Galeas; Morgan Truitt; Cameron Pitt; Anatoly Urisman; Sourav Bandyopadhyay; Davide Ruggero; Frank McCormick
Journal:  Cancer Res       Date:  2015-05-14       Impact factor: 12.701

4.  Differential response to ablative ionizing radiation in genetically distinct non-small cell lung cancer cells.

Authors:  Ayman Oweida; Zeinab Sharifi; Hani Halabi; Yaoxian Xu; Siham Sabri; Bassam Abdulkarim
Journal:  Cancer Biol Ther       Date:  2016-04-02       Impact factor: 4.742

5.  Hypofractionated Accelerated Chemo-radiotherapy (Chemo-HypoAR) With Cisplatin and Liposomal Doxorubicin for the Treatment of Patients With Uterine Sarcomas.

Authors:  Spyros Domoxoudis; Ioannis M Koukourakis; Axiotis G Giakzidis; Michael I Koukourakis
Journal:  In Vivo       Date:  2019 Sep-Oct       Impact factor: 2.155

Review 6.  Regulation of homeostasis and oncogenesis in the intestinal epithelium by Ras.

Authors:  Sergia Velho; Kevin M Haigis
Journal:  Exp Cell Res       Date:  2011-06-17       Impact factor: 3.905

Review 7.  Altering the response to radiation: sensitizers and protectors.

Authors:  Deborah E Citrin; James B Mitchell
Journal:  Semin Oncol       Date:  2014-10-07       Impact factor: 4.929

8.  A phase I study of nelfinavir concurrent with temozolomide and radiotherapy in patients with glioblastoma multiforme.

Authors:  Michelle Alonso-Basanta; Penny Fang; Amit Maity; Stephen M Hahn; Robert A Lustig; Jay F Dorsey
Journal:  J Neurooncol       Date:  2013-11-06       Impact factor: 4.130

Review 9.  Basic mechanisms of therapeutic resistance to radiation and chemotherapy in lung cancer.

Authors:  Henning Willers; Christopher G Azzoli; Wil L Santivasi; Fen Xia
Journal:  Cancer J       Date:  2013 May-Jun       Impact factor: 3.360

10.  A method for the second-site screening of K-Ras in the presence of a covalently attached first-site ligand.

Authors:  Qi Sun; Jason Phan; Anders R Friberg; DeMarco V Camper; Edward T Olejniczak; Stephen W Fesik
Journal:  J Biomol NMR       Date:  2014-08-03       Impact factor: 2.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.